Navigation Links
BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Date:10/27/2008

EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. released two new Nephrology TreatmentTrends(TM) publications based on survey results from 204 Nephrologists and 201 Renal Dietitians in the US. Renal Dietitians (RDs) are an integral part of the management of dialysis patients, particularly in their role recommending and reinforcing adherence with Phosphate Binders, Active Vitamin D, and Calcimimetic agents.

In the phosphate binder market, the introduction of Genzyme's Renvela has given overall sevelamer share a boost compared to the same quarter last year, although most of the patients on Renvela have been switched from Renagel. Close to two-thirds of MDs and over three quarters of RDs have used Renvela in their hemodialysis patients, however, Renagel and FMC's PhosLo remain the two most frequently prescribed binders among dialysis patients. While sevelamer has the highest share across all types of dialysis units, Shire's Fosrenol does its best in Davita units whereas PhosLo does its best in Fresenius units. Nephrologists are divided as to their first line preference in dialysis -- approximately half choose a calcium-based binder and half choose a non-calcium based binder compared to over two-thirds of RDs who choose to start with a non-calcium based binder. In patients with Chronic Kidney Disease not on dialysis (CKD), 73% of Nephrologists prefer to start with calcium-based binders.

In the PTH modifier market, although RDs report a high level of influence in the choice of Vitamin D, approximately 80% report that their dialysis center generally encourages the use of Abbott's Zemplar, compared to only 29% who report they are encouraged to use Genzyme's Hectorol. While Zemplar IV is the overwhelming market share leader in hemodialysis and leads in every type of dialysis unit, Hectorol does its best in non-chains and its worst in Davita. In CKD, Nephrologists continue to use oral calcitriol most often. Compared to the prior year, RDs report a high and growing influence in decisions regarding the use of Sensipar. Treatment prevalence with Sensipar in hemodialysis patients, according to both MDs and RDs has been lingering at around 30%. While Sensipar is often used second line to Vitamin D, it does seem to impact Vitamin D dose, with the majority of RDs reporting that patients on Sensipar tend to be on lower doses of Vitamin D.

In the renal anemia market, Nephrologists seem to be settling into the new treatment standards (e.g., lower target hemoglobin levels, lower levels for ESA initiation, holds, and dose reductions) and more than two-thirds do not anticipate making any additional changes to their use of ESAs in CKD or dialysis. While Amgen's Epogen continues to dominate the dialysis market, there did seem to be some brand shifting between Amgen's Aranesp and Ortho Biotech's Procrit in CKD. Nephrologists do not predict significant changes in ESA market share in CKD or dialysis in the near-term, but they do project that bundling will have an impact on ESA use most likely through shifts to subcutaneous dosing and less aggressive treatment of EPO hypo-responders. New ESAs in development could also shift market dynamics particularly if these products are able to meet what Nephrologists identified as the most desired attributes in a new ESA.

In terms of IV iron, American Regent's Venofer remains the market leader in both dialysis and CKD, however, office-based Nephrologists report significantly higher CKD share for Venofer and hospital-based Nephrologists report significantly higher CKD share for Watson's Ferrlecit. In the dialysis market, very little brand switching took place in the past year, although 60% of Nephrologists primarily affiliated with Fresenius units expect their use of Venofer to increase following the news that Fresenius will be marketing and distributing Venofer in dialysis units. Awareness of AMAG Pharmaceutical's Ferumoxytol continues to be low. Among those familiar with the product, expected benefits center around dosing and administration, particularly for CKD patients. More than half of Nephrologists believe that the introduction of this new product will lead to an overall increase in their use of IV iron in CKD.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

CONTACT:

Jennifer Robinson

BioTrends Research Group, Inc.,

610-363-3872


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
2. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
3. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
5. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
7. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
8. BioWisdom Releases Text Analytics Version of OmniViz for Patent Specialists
9. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
10. Presidio Pay Advisors Releases Salary GPS Tool
11. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... 19, 2017 , ... EDETEK, Inc., a clinical technology company ... launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and ... 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... and commercialization, has just announced two more sessions of its “From the Helm” ... focus on the world of online templates for design control exercises. Led by ...
(Date:6/15/2017)... ... June 15, 2017 , ... New resistant soybean ... options for managing Palmer amaranth and other broadleaf weeds resistant to glyphosate. But ... necessary. Auxin herbicides are known to drift and to cause harm to sensitive, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):